Protara Therapeutics Inc
TARA
Get informed when a big investor buys or sells
+ FollowMarket Cap$214.7M
Close$
$1.08
72.6% downside
Current Fair Value
72.6% downsideOvervalued by 72.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $214.70 Million |
|---|---|
| Enterprise Value | $200.37 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.34 |
| Beta | 1.49 |
| Outstanding Shares | 61,006,766 |
Return
| Return on Equity | -43.40% |
|---|---|
| Return on Assets | -39.76% |
| Return on Invested Capital | -44.37% |
Valuation & Multiples
| P/E Ratio | -2.81 |
|---|---|
| PEG | -6.26 |
| Price to Sales | - |
| Price to Book Ratio | 1.97 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.77 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 24.29% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 22,900▼ 46.74% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 107.95%▲ 1.59% |
|---|---|
| Total Invested | $177.37M▼ 25.28% |
| Investors Holding | 123▲ 5.00% |
ESG Score
No data
About Protara Therapeutics Inc
CEO: Jesse Shefferman